Companies › Lallemand Health Solutions
2 active drug programs in 3 registered trials: 3 Phase 2; Other, Metabolic and endocrine; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| B. lactis B94 Probiotic (Bifidobacterium lactis B94) | – | Phase 2 | Infantile Colic | Feb 2027 |
| Probiotic Formula 1 Orally delivered probiotic formula | – | Phase 2 | Focus is on Healthy Subjects; Obesity and Overweight | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07246161 | Probiotic Formula 1 | Phase 2 | Focus is on Healthy Subjects | Other | Oct 2026 |
| NCT06385054 | B. lactis B94 | Phase 2 | Infantile Colic | Other | Feb 2027 |
| NCT06786052 | Probiotic Formula 1 | Phase 2 | Obesity and Overweight | Metabolic and endocrine | Feb 2028 |
No annotated target.
–
Photozig MaaT Pharma Serum Life Science Europe Distribuidora Biolife SA de CV Circul'Egg
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.